Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05021991 · ClinicalTrials.gov registry record · Phase 2

A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor

A Phase 2 study, sponsored by Praxis Precision Medicines.

Completed
Registry status
Phase 2
Development phase
133
Enrollment target

NCT05021991 is a Phase 2 study that has completed, run by Praxis Precision Medicines. The registered enrollment target is 133 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05021991, a Phase 2 study, has completed, sponsored by Praxis Precision Medicines.

COMPLETED
Registry status
Phase 2
Development phase
133 participants
Enrollment target

Study Summary

This multi-center, randomized, double-blinded, placebo-controlled, dose-range-finding clinical trial (with an optional Extension comprised of an Extension Double-blind (DB) Lead in Period followed by an Extension Open-label (OL) Period) that will assess the efficacy, safety, and tolerability of PRAX 944 in participants aged 18 years or older who have a diagnosis of Essential Tremor (ET) and have had symptoms for at least 3 years.

Interventions

  • DRUG Placebo
  • DRUG 100 mg PRAX-944
  • DRUG 60 mg PRAX-944
  • DRUG Flexibly dosed 20 mg to 100 mg PRAX-944

Trial Details

FieldValue
Enrollment Target 133 participants
Start Date 2021-10-14
Est. Completion 2024-02-29
Phase Phase 2

Sponsor

Praxis Precision Medicines

13 total trials

What the Registry Record Tells You About NCT05021991

The ClinicalTrials.gov registry entry for NCT05021991 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Praxis Precision Medicines, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT05021991 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05021991 about?

NCT05021991 is a clinical study titled "A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor". This multi-center, randomized, double-blinded, placebo-controlled, dose-range-finding clinical trial (with an optional Extension comprised of an Extension Double-blind (DB) Lead in Period followed by an Extension Open-label (OL) Period) that will assess the efficacy, safety, and tolerability of PRAX...

What is the current status of trial NCT05021991?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2021-10-14. Estimated completion is 2024-02-29.

What interventions are being tested in trial NCT05021991?

The interventions under investigation include: Placebo (DRUG), 100 mg PRAX-944 (DRUG), 60 mg PRAX-944 (DRUG), Flexibly dosed 20 mg to 100 mg PRAX-944 (DRUG).

Who is sponsoring clinical trial NCT05021991?

This trial is sponsored by Praxis Precision Medicines, which has 13 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.